A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)

Inclusion Criteria:

• Participants meet the diagnosis of moderate to severe Crohn's disease.

• Participants prescribed with Humira, under investigators' sufficient considerationof benefits/ risks per local label.

Exclusion Criteria:

• Participants who have any of the contraindications as per adalimumab (Humira) labelin China.

• Participants who are allergic to any component of adalimumab (Humira).

• Participants with active hepatitis B diagnosed.

• Participants with severe active infection, or known history of active or latenttuberculosis (TB), or latent TB infection with inadequate treatment.

• Participants with cancer diagnosed, excluding also those with non-melanoma skincancer (NMSC) completely treated, per local label.

• Participants with moderate to severe heart failure.

• Participants who are unwilling to participate, or not suitable for participation asjudged by the investigator at risk of noncompliance to study procedure.

• Participants who are enrolled to other interventional studies.

• Participants who are prescribed with adalimumab but choose Humira bio-similar inChina.